ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Flexible-Dose Vardenafil in a Community-Based Population of Men Affected by Erectile Dysfunction: A 12-Week Open-Label, Multicenter Trial
Article first published online: 6 OCT 2005
The Journal of Sexual Medicine
Volume 2, Issue 6, pages 842–847, November 2005
How to Cite
Mirone, V., Palmieri, A., Cucinotta, D., Parazzini, F., Morelli, P., Bettocchi, C., Fusco, F. and Montorsi, F. (2005), ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Flexible-Dose Vardenafil in a Community-Based Population of Men Affected by Erectile Dysfunction: A 12-Week Open-Label, Multicenter Trial. Journal of Sexual Medicine, 2: 842–847. doi: 10.1111/j.1743-6109.2005.00138.x
- Issue published online: 6 OCT 2005
- Article first published online: 6 OCT 2005
- Erectile Dysfunction;
- Global Assessment Question;
- International Index of Erectile Function
Aim To evaluate the efficacy, safety, and tolerability of a flexible-dose regimen of vardenafil in a community-based population of men with erectile dysfunction (ED).
Methods This was a 12-week, open-label, flexible-dose, multicenter study of unselected men with ED of diverse origins and severity. Unlike previous studies, prostatectomy-induced ED and previous unresponsiveness to sildenafil were not exclusion criteria. After 4 weeks of treatment with 10 mg of vardenafil, the dose could be continued or titrated to 5 mg or 20 mg, depending on efficacy and tolerability. After 8 weeks, another dose change was possible. Efficacy was assessed with International Index of Erectile Function erectile function (IIEF-EF) domain scores, diary questions of the Sexual Encounter Profile (SEP), and a global assessment question (GAQ) about erection improvement during the previous 4 weeks.
Results Safety was evaluated in 497 patients, and 480 were suitable for intention-to-treat analysis. After 12 weeks of treatment, the mean per patient rate of successful intercourse, defined by an affirmative response to SEP questions 1–3, was 72%, and was related to age and ED duration. The overall success rate increased from 66% at week 4 to 77% at week 12. The mean IIEF-EF domain score of the whole population increased from 17.2 (baseline) to 24.4 (endpoint). At week 12, the best scores were obtained by patients taking 5 mg and 10 mg. At week 12, GAQ scores showed improved erection in 97.4%, 94.8%, and 78.8% of patients in the 5 mg, 10 mg, and 20 mg group, respectively. Safety was excellent: no serious drug-related event was reported, and only 2.2% of patients discontinued treatment because of side-effects.
Conclusions Vardenafil was effective and well tolerated in this community-based ED population that is truly representative of the general ED population. Dose titration meets the patient's needs and optimizes clinical outcome. Mirone V, Palmieri A, Cucinotta D, Parazzini F, Morelli P, Bettocchi C, Fusco F, and Montorsi F. Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial. J Sex Med 2005;2:842–847.